entacapone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
catechol-O-methyltransferase (COMT) inhibitors 1018 130929-57-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • entacapone
  • entacom
  • comtess
Entacapone is a selective and reversible inhibitor of COMT. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, and epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. When entacapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are greater and more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that at a given frequency of levodopa administration, these more sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease.
  • Molecular weight: 305.29
  • Formula: C14H15N3O5
  • CLOGP: 2.66
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 2
  • TPSA: 130.38
  • ALOGS: -3.58
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 87.35 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 42 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 19, 1999 FDA ORION PHARMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 429.87 23.50 139 4217 27722 50573046
Hallucination 252.78 23.50 108 4248 46549 50554219
On and off phenomenon 146.58 23.50 32 4324 1380 50599388
Hallucination, visual 143.94 23.50 54 4302 16528 50584240
Dystonia 111.39 23.50 41 4315 11885 50588883
Psychotic disorder 106.46 23.50 47 4309 21765 50579003
Therapeutic response shortened 98.07 23.50 33 4323 7356 50593412
Compulsive shopping 95.70 23.50 20 4336 698 50600070
Sudden onset of sleep 95.62 23.50 19 4337 513 50600255
Impulse-control disorder 91.25 23.50 19 4337 651 50600117
Mutism 87.83 23.50 21 4335 1360 50599408
Delusion 86.53 23.50 33 4323 10536 50590232
Dopamine dysregulation syndrome 74.85 23.50 13 4343 163 50600605
Acute psychosis 68.62 23.50 19 4337 2201 50598567
Muscle rigidity 67.43 23.50 27 4329 9802 50590966
Akinesia 61.28 23.50 16 4340 1483 50599285
Stereotypy 58.85 23.50 12 4344 370 50600398
Freezing phenomenon 57.18 23.50 14 4342 1001 50599767
Camptocormia 55.60 23.50 11 4345 290 50600478
Tremor 52.98 23.50 57 4299 114846 50485922
Dysphagia 49.66 23.50 46 4310 77472 50523296
Orthostatic hypotension 49.22 23.50 31 4325 29450 50571318
Fall 47.62 23.50 95 4261 334837 50265931
Gambling 45.87 23.50 9 4347 227 50600541
Parkinsonian gait 45.77 23.50 10 4346 432 50600336
Gait disturbance 45.34 23.50 60 4296 149945 50450823
Confusional state 43.80 23.50 66 4290 185862 50414906
Impulsive behaviour 42.87 23.50 12 4344 1446 50599322
Agitation 42.82 23.50 36 4320 53348 50547420
Aggression 42.41 23.50 25 4331 21091 50579677
Hyperkinesia 38.39 23.50 11 4345 1441 50599327
Therapeutic product effect variable 36.79 23.50 10 4346 1080 50599688
Pleurothotonus 35.04 23.50 10 4346 1291 50599477
Wrong technique in product usage process 33.72 23.50 32 4324 55478 50545290
Neuroleptic malignant syndrome 32.88 23.50 17 4339 11113 50589655
Gambling disorder 31.36 23.50 9 4347 1185 50599583
Stoma site discharge 30.78 23.50 9 4347 1266 50599502
Eating disorder 30.30 23.50 18 4338 15391 50585377
Stoma site erythema 29.26 23.50 8 4348 883 50599885
Delirium 29.06 23.50 25 4331 38167 50562601
Bradykinesia 27.62 23.50 11 4345 3932 50596836
Rash 27.21 23.50 3 4353 437468 50163300
Parkinson's disease 26.94 23.50 8 4348 1187 50599581
Femoral neck fracture 26.71 23.50 13 4343 7477 50593291
Posture abnormal 26.41 23.50 9 4347 2080 50598688
Abnormal behaviour 26.28 23.50 18 4338 19640 50581128
Balance disorder 25.67 23.50 31 4325 70559 50530209
Parkinsonism hyperpyrexia syndrome 25.30 23.50 5 4351 131 50600637
Ileus 24.83 23.50 15 4341 13214 50587554
Parkinsonism 24.67 23.50 13 4343 8834 50591934
Somnolence 24.40 23.50 46 4310 154939 50445829
Teeth brittle 23.76 23.50 6 4350 487 50600281

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 270.13 22.63 116 6301 19945 29548165
Hallucination 269.25 22.63 149 6268 44563 29523547
Hypersexuality 227.99 22.63 54 6363 1302 29566808
Hallucination, visual 209.21 22.63 89 6328 14926 29553184
Gambling disorder 204.82 22.63 51 6366 1524 29566586
On and off phenomenon 189.79 22.63 50 6367 1878 29566232
Muscle rigidity 162.28 22.63 65 6352 9346 29558764
Delusion 116.02 22.63 54 6363 11162 29556948
Freezing phenomenon 115.93 22.63 31 6386 1232 29566878
Dysphagia 98.31 22.63 87 6330 54839 29513271
Parkinson's disease 95.27 22.63 27 6390 1334 29566776
Fall 92.27 22.63 149 6268 177029 29391081
Dopamine dysregulation syndrome 76.13 22.63 17 6400 312 29567798
Neuroleptic malignant syndrome 68.44 22.63 43 6374 16105 29552005
Akinesia 64.95 22.63 22 6395 1968 29566142
Bradykinesia 63.53 22.63 25 6392 3422 29564688
Tremor 58.87 22.63 76 6341 73462 29494648
Cognitive disorder 58.22 22.63 45 6372 23454 29544656
Impulse-control disorder 58.17 22.63 18 6399 1207 29566903
Dementia 54.36 22.63 33 6384 11625 29556485
Confusional state 51.27 22.63 96 6321 127781 29440329
Gait disturbance 48.35 22.63 69 6348 73280 29494830
Aggression 47.61 22.63 48 6369 35493 29532617
Paranoia 43.60 22.63 27 6390 9850 29558260
Agitation 42.55 22.63 54 6363 51250 29516860
Stoma site discharge 41.55 22.63 13 6404 904 29567206
Device dislocation 41.28 22.63 20 6397 4507 29563603
Reduced facial expression 40.50 22.63 12 6405 694 29567416
Therapeutic response shortened 40.21 22.63 20 6397 4771 29563339
Compulsive shopping 37.71 22.63 10 6407 384 29567726
Persecutory delusion 37.60 22.63 15 6402 2126 29565984
Pneumonia aspiration 37.54 22.63 43 6374 36694 29531416
Stereotypy 36.92 22.63 11 6406 648 29567462
Delirium 36.74 22.63 44 6373 39353 29528757
Therapeutic product effect variable 35.95 22.63 14 6403 1863 29566247
Psychotic disorder 35.85 22.63 32 6385 20322 29547788
Posture abnormal 35.45 22.63 14 6403 1933 29566177
Therapeutic product effect decreased 34.44 22.63 37 6380 29414 29538696
Jealous delusion 33.40 22.63 8 6409 202 29567908
Sudden onset of sleep 33.32 22.63 9 6408 371 29567739
Abnormal behaviour 32.36 22.63 32 6385 23095 29545015
Obsessive-compulsive disorder 32.30 22.63 17 6400 4559 29563551
Hyperkinesia 30.88 22.63 12 6405 1587 29566523
Stoma site pain 30.55 22.63 9 6408 510 29567600
Device issue 28.71 22.63 19 6398 7761 29560349
Somnolence 28.61 22.63 63 6354 93892 29474218
Illusion 27.87 22.63 9 6408 693 29567417
Somatic delusion 27.58 22.63 6 6411 97 29568013
Tricuspid valve sclerosis 27.46 22.63 5 6412 30 29568080
Mitral valve sclerosis 26.87 22.63 6 6411 110 29568000
Balance disorder 26.75 22.63 36 6381 36134 29531976
Mobility decreased 26.03 22.63 30 6387 25750 29542360
Abnormal dreams 25.78 22.63 17 6400 6903 29561207
Progressive supranuclear palsy 25.39 22.63 5 6412 48 29568062
Gastric fistula 23.59 22.63 5 6412 71 29568039
Parkinsonism hyperpyrexia syndrome 22.86 22.63 5 6412 83 29568027

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dyskinesia 554.59 23.06 204 8207 39184 64451137
Hallucination 375.77 23.06 185 8226 72603 64417718
Hallucination, visual 314.81 23.06 123 8288 27711 64462610
On and off phenomenon 258.22 23.06 61 8350 2458 64487863
Hypersexuality 245.01 23.06 53 8358 1426 64488895
Gambling disorder 205.32 23.06 48 8363 1846 64488475
Muscle rigidity 162.07 23.06 67 8344 17406 64472915
Delusion 146.78 23.06 63 8348 17951 64472370
Impulse-control disorder 129.56 23.06 32 8379 1556 64488765
Therapeutic response shortened 125.72 23.06 48 8363 10122 64480199
Dopamine dysregulation syndrome 124.90 23.06 25 8386 454 64489867
Psychotic disorder 118.55 23.06 67 8344 34511 64455810
Dystonia 115.41 23.06 54 8357 18811 64471510
Freezing phenomenon 110.39 23.06 28 8383 1518 64488803
Compulsive shopping 107.36 23.06 24 8387 753 64489568
Akinesia 104.20 23.06 31 8380 3048 64487273
Dysphagia 95.97 23.06 92 8319 106720 64383601
Parkinson's disease 94.88 23.06 25 8386 1576 64488745
Stereotypy 94.74 23.06 22 8389 820 64489501
Fall 94.50 23.06 183 8228 416643 64073678
Neuroleptic malignant syndrome 92.66 23.06 51 8360 24945 64465376
Sudden onset of sleep 85.36 23.06 19 8392 584 64489737
Confusional state 84.22 23.06 134 8277 261010 64229311
Aggression 79.50 23.06 58 8353 46174 64444147
Agitation 79.13 23.06 76 8335 88291 64402030
Bradykinesia 77.63 23.06 30 8381 6530 64483791
Tremor 75.93 23.06 95 8316 148135 64342186
Mutism 75.49 23.06 22 8389 2012 64488309
Therapeutic product effect variable 70.95 23.06 20 8391 1624 64488697
Gait disturbance 70.70 23.06 99 8312 172056 64318265
Acute psychosis 62.25 23.06 22 8389 3730 64486591
Delirium 60.96 23.06 59 8352 69135 64421186
Hyperkinesia 58.25 23.06 19 8392 2527 64487794
Cognitive disorder 54.30 23.06 50 8361 55037 64435284
Orthostatic hypotension 53.16 23.06 46 8365 46692 64443629
Abnormal behaviour 52.89 23.06 40 8371 33582 64456739
Camptocormia 51.12 23.06 12 8399 469 64489852
Persecutory delusion 49.14 23.06 19 8392 4139 64486182
Parkinsonian gait 49.08 23.06 13 8398 836 64489485
Parkinsonism hyperpyrexia syndrome 48.13 23.06 10 8401 220 64490101
Dementia 47.33 23.06 31 8380 20735 64469586
Gambling 45.85 23.06 10 8401 279 64490042
Posture abnormal 45.42 23.06 17 8394 3389 64486932
Stoma site discharge 44.42 23.06 14 8397 1668 64488653
Progressive supranuclear palsy 42.54 23.06 8 8403 103 64490218
Paranoia 41.19 23.06 26 8385 16326 64473995
Blood creatine phosphokinase increased 40.77 23.06 44 8367 58514 64431807
Reduced facial expression 37.39 23.06 13 8398 2100 64488221
Illusion 37.06 23.06 12 8399 1558 64488763
Torticollis 37.01 23.06 13 8398 2164 64488157
Pneumonia aspiration 36.89 23.06 42 8369 59229 64431092
Jealous delusion 36.83 23.06 8 8403 219 64490102
Arthralgia 36.06 23.06 7 8404 442253 64048068
Device issue 35.74 23.06 27 8384 22621 64467700
Impulsive behaviour 34.45 23.06 13 8398 2650 64487671
Resting tremor 34.17 23.06 11 8400 1403 64488918
Parkinsonism 34.08 23.06 22 8389 14351 64475970
Gastric fistula 33.78 23.06 7 8404 152 64490169
Wrong technique in product usage process 33.77 23.06 42 8369 64932 64425389
Depressed level of consciousness 30.67 23.06 45 8366 81391 64408930
Somnolence 30.61 23.06 76 8335 203569 64286752
Obsessive-compulsive disorder 30.09 23.06 14 8397 4804 64485517
Tricuspid valve sclerosis 30.00 23.06 5 8406 30 64490291
Nightmare 28.72 23.06 23 8388 20970 64469351
Restlessness 27.87 23.06 30 8381 39755 64450566
Femoral neck fracture 27.45 23.06 16 8395 8708 64481613
Deep brain stimulation 27.15 23.06 5 8406 57 64490264
Mania 26.99 23.06 20 8391 16266 64474055
Balance disorder 26.85 23.06 43 8368 83883 64406438
Anxiety 25.72 23.06 71 8340 202578 64287743
Pleurothotonus 25.37 23.06 10 8401 2292 64488029
Obsessive thoughts 24.93 23.06 8 8403 1009 64489312
Abnormal dreams 24.92 23.06 16 8395 10340 64479981
Immobile 24.30 23.06 13 8398 6002 64484319
Stoma site pain 24.09 23.06 8 8403 1125 64489196
Nocturia 23.82 23.06 16 8395 11149 64479172
Hyperpyrexia 23.44 23.06 12 8399 5065 64485256
Stoma site erythema 23.38 23.06 8 8403 1231 64489090
Hyperthermia 23.34 23.06 18 8393 15532 64474789
Headache 23.19 23.06 21 8390 529446 63960875

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04BX02 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Other dopaminergic agents
CHEBI has role CHEBI:35470 central nervous system agents
CHEBI has role CHEBI:48406 catechol O-methyltransferase inhibitors
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:66956 antidyskinetic agent
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D065098 Catechol O-Methyltransferase Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
FDA MoA N0000175756 Catechol O-Methyltransferase Inhibitors
FDA EPC N0000175757 Catechol-O-Methyltransferase Inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Parkinson's disease indication 49049000 DOID:14330
Suicidal thoughts contraindication 6471006
Hallucinations contraindication 7011001
Dyskinesia contraindication 9748009
Peptic ulcer contraindication 13200003 DOID:750
Disorder of lung contraindication 19829001 DOID:850
Myocardial infarction contraindication 22298006 DOID:5844
Orthostatic hypotension contraindication 28651003
Obstruction of bile duct contraindication 30144000
Depressive disorder contraindication 35489007
Conduction disorder of the heart contraindication 44808001
Duodenal ulcer disease contraindication 51868009 DOID:1724
Diarrhea contraindication 62315008
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Acute disease of cardiovascular system contraindication 128487001
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Disease of liver contraindication 235856003 DOID:409
Retention of urine contraindication 267064002
Psychoneurotic personality disorder contraindication 268634009
Malignant melanoma contraindication 372244006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.41 acidic
pKa2 13.34 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Catechol O-methyltransferase Enzyme INHIBITOR Ki 9.52 SCIENTIFIC LITERATURE CHEMBL
G-protein coupled receptor 35 GPCR EC50 5.25 CHEMBL
Alpha-ketoglutarate-dependent dioxygenase FTO Unclassified IC50 5.52 CHEMBL
Catechol O-methyltransferase Enzyme IC50 7.89 CHEMBL

External reference:

IDSource
4021181 VUID
N0000148629 NUI
D00781 KEGG_DRUG
4021181 VANDF
C0165921 UMLSCUI
CHEBI:4798 CHEBI
PD9 PDB_CHEM_ID
CHEMBL953 ChEMBL_ID
DB00494 DRUGBANK_ID
C071192 MESH_SUPPLEMENTAL_RECORD_UI
5281081 PUBCHEM_CID
6647 IUPHAR_LIGAND_ID
6812 INN_ID
4975G9NM6T UNII
227109 RXNORM
66346 MMSL
8477 MMSL
d04460 MMSL
007684 NDDF
116116003 SNOMEDCT_US
387018000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Comtan HUMAN PRESCRIPTION DRUG LABEL 1 0078-0327 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0407 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0408 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0409 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0527 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0544 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Stalevo HUMAN PRESCRIPTION DRUG LABEL 3 0078-0545 TABLET, FILM COATED 200 mg ORAL NDA 25 sections
Carbidopa, Levodopa and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0378-8300 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 24 sections
Carbidopa, Levodopa and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0378-8301 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 24 sections
Carbidopa, Levodopa and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0378-8302 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 24 sections
Carbidopa, Levodopa and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0378-8303 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 24 sections
Carbidopa, Levodopa and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0378-8304 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 24 sections
Carbidopa, Levodopa and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0378-8305 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 24 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0378-9080 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 21 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0527-1830 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0615-8298 TABLET 200 mg ORAL ANDA 19 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0781-5578 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 13 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5613 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5625 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5637 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5641 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5654 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Carbidopa, Levodopa, and Entacapone HUMAN PRESCRIPTION DRUG LABEL 3 0781-5669 TABLET, FILM COATED 200 mg ORAL NDA authorized generic 26 sections
Entacapone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6822 TABLET, FILM COATED 200 mg ORAL ANDA 20 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-689 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-690 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-691 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-692 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-693 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
CARBIDOPA, LEVODOPA AND ENTACAPONE Human Prescription Drug Label 3 16571-694 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections